Compare Gilead Sciences, Inc. (GILD) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs TKO Group Holdings Inc — how do they compare? Gilead Sciences, Inc. trades at $136.36 (market cap $163.51B), while TKO Group Holdings Inc trades at $184.4 (market cap $13.92B). The key difference: Gilead Sciences, Inc. is far larger — about 11.7× TKO Group Holdings Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | TKO | |
|---|---|---|
Market Cap | $163.51B | $13.92B |
Sector | Health | Technology |
52-Week High | $155.80 | $224.96 |
52-Week Low | $108.22 | $155.61 |
Enterprise Value | $178.05B | $18.10B |
Dividend Yield | 2.49% | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
TKO trades at $182.895, down 0.9% on the day, with a bearish technical signal despite strong analyst support. The company shows solid revenue growth from $4.74B in 2025 to $5.1B projected for 2026, though net margins remain modest at 4.47%. Recent developments include successful international events and an $800 million share repurchase, while technical indicators show support at $180 and resistance at $188.
The stock presents a mixed outlook with strong Wall Street bullishness (89% buy ratings) and a $228.40 price target offering 25% upside potential. However, elevated P/E ratio of 69.03 and recent earnings misses create valuation concerns. Key risks include execution challenges in monetizing live events and competitive pressures in sports entertainment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
